{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T07:26:45Z","timestamp":1790407605725,"version":"4.1.0"},"reference-count":21,"publisher":"American Academy of Pediatrics (AAP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2003,10,1]]},"abstract":"<jats:p>Objective. To quantify the risk of anaphylaxis after vaccination of children and adolescents.<\/jats:p>\n               <jats:p>Methods. The study population consisted of children and adolescents who were enrolled at 4 health maintenance organizations that participated in the Vaccine Safety Datalink Project. For the period 1991\u20131997, we identified potential cases by searching for occurrences of International Classification of Diseases, Ninth Revision (ICD-9) code 995.0 (anaphylactic shock), E948.0 through E948.9 (adverse reaction from bacterial vaccines), and E949.0 through E949.9 (adverse reaction from other vaccines and biological substances). At 1 study site, we also included a range of other allergy codes. We restricted to diagnoses on days 0 to 2 after vaccination (ICD-9 995.0) or day 0 (all other ICD-9 codes). We then reviewed the medical record to confirm the diagnosis.<\/jats:p>\n               <jats:p>Results. We identified 5 cases of potentially vaccine-associated anaphylaxis after administration of 7 644 049 vaccine doses, for a risk of 0.65 cases\/million doses (95% confidence interval: 0.21\u20131.53). None of the episodes resulted in death. Vaccines that were administered before the anaphylactic episodes were generally given in combination and included measles-mumps-rubella, hepatitis B, diphtheria-tetanus, diphtheria-tetanus-pertussis, Haemophilus influenzae type b, and oral polio vaccine. One case of anaphylaxis followed measles-mumps-rubella vaccine alone. At the site at which we reviewed additional allergy codes, we identified 1 case after 653 990 vaccine doses, for a risk of 1.53 cases\/million doses (95% confidence interval: 0.04\u20138.52).<\/jats:p>\n               <jats:p>Conclusions. Patients and health care providers can be reassured that vaccine-associated anaphylaxis is a rare event. Nevertheless, providers should be prepared to provide immediate medical treatment should it occur.<\/jats:p>","DOI":"10.1542\/peds.112.4.815","type":"journal-article","created":{"date-parts":[[2004,8,14]],"date-time":"2004-08-14T00:43:47Z","timestamp":1092444227000},"page":"815-820","source":"Crossref","is-referenced-by-count":271,"title":["Risk of Anaphylaxis After Vaccination of Children and Adolescents"],"prefix":"10.1542","volume":"112","author":[{"given":"Kari","family":"Bohlke","sequence":"first","affiliation":[{"name":"Center for Health Studies, Group Health Cooperative, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Davis","sequence":"additional","affiliation":[{"name":"Center for Health Studies, Group Health Cooperative, Seattle, Washington"},{"name":"Departments of Pediatrics and Epidemiology, University of Washington Schools of Medicine and Public Health, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. M.","family":"Marcy","sequence":"additional","affiliation":[{"name":"Kaiser Foundation Hospital, Panorama City, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. M.","family":"Braun","sequence":"additional","affiliation":[{"name":"Division of Epidemiology, Office of Biostatistics and Epidemiology, Center for Biologics Evaluation and Research, Food and Drug Administration, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"DeStefano","sequence":"additional","affiliation":[{"name":"National Immunization Program, Centers for Disease Control and Prevention, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven B.","family":"Black","sequence":"additional","affiliation":[{"name":"Pediatric Vaccine Study Center, Northern California Kaiser Permanente, Oakland, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Mullooly","sequence":"additional","affiliation":[{"name":"Center for Health Research, Northwest Kaiser Permanente, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Thompson","sequence":"additional","affiliation":[{"name":"Department of Preventive Care, Group Health Cooperative, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Vaccine Safety Datalink Team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2003,10,1]]},"reference":[{"key":"2021121003422376700_R1","unstructured":"Stratton KR, Howe CJ, Johnston RB, eds. Adverse Events Associated With Childhood Vaccines: Evidence Bearing on Causality. Washington, DC: National Academy Press; 1994"},{"key":"2021121003422376700_R2","doi-asserted-by":"crossref","unstructured":"Mullooly J, Drew L, DeStefano F, et al. Quality of HMO vaccination databases used to monitor childhood vaccine safety. Vaccine Safety DataLink Team. Am J Epidemiol.1999;149:186\u2013194","DOI":"10.1093\/oxfordjournals.aje.a009785"},{"key":"2021121003422376700_R3","unstructured":"Blumenthal MN. Principles of genetics. In: Middleton E, Ellis EF, Yunginger JW, Reed CE, Adkinson NF, Busse WW, eds. Allergy: Principles and Practice. 5th ed. St Louis, MO: Mosby Inc; 1998:28\u201339"},{"key":"2021121003422376700_R4","doi-asserted-by":"crossref","unstructured":"Chen RT, Rastogi SC, Mullen JR, et al. The Vaccine Adverse Event Reporting System (VAERS). Vaccine.1994;12:542\u2013550","DOI":"10.1016\/0264-410X(94)90315-8"},{"key":"2021121003422376700_R5","doi-asserted-by":"crossref","unstructured":"Klein JS, Yocum MW. Underreporting of anaphylaxis in a community emergency room. J Allergy Clin Immunol.1995;95:637\u2013638","DOI":"10.1016\/S0091-6749(95)70329-2"},{"key":"2021121003422376700_R6","doi-asserted-by":"crossref","unstructured":"van der Klauw MM, Stricker BH, Herings RM, Cost WS, Valkenburg HA, Wilson JH. A population based case-cohort study of drug-induced anaphylaxis. Br J Clin Pharmacol.1993;35:400\u2013408","DOI":"10.1111\/j.1365-2125.1993.tb04157.x"},{"key":"2021121003422376700_R7","doi-asserted-by":"crossref","unstructured":"Patja A, Davidkin I, Kurki T, Kallio MJ, Valle M, Peltola H. Serious adverse events after measles-mumps-rubella vaccination during a fourteen-year prospective follow-up. Pediatr Infect Dis J.2000;19:1127\u20131134","DOI":"10.1097\/00006454-200012000-00002"},{"key":"2021121003422376700_R8","doi-asserted-by":"crossref","unstructured":"Pool V, Braun MM, Kelso JM, et al. Prevalence of anti-gelatin IgE antibodies in people with anaphylaxis after measles-mumps rubella vaccine in the United States. Pediatrics.2002;110(6). Available at: http:\/\/www.pediatrics.org\/cgi\/content\/full\/110\/6\/e71","DOI":"10.1542\/peds.110.6.e71"},{"key":"2021121003422376700_R9","unstructured":"D\u2019Souza RM, Campbell-Lloyd S, Isaacs D, et al. Adverse events following immunisation associated with the 1998 Australian Measles Control Campaign. Commun Dis Intell.2000;24:27\u201333"},{"key":"2021121003422376700_R10","doi-asserted-by":"crossref","unstructured":"Dobson S, Scheifele D, Bell A. Assessment of a universal, school-based hepatitis B vaccination program. JAMA.1995;274:1209\u20131213","DOI":"10.1001\/jama.274.15.1209"},{"key":"2021121003422376700_R11","unstructured":"Update: vaccine side effects, adverse reactions, contraindications, and precautions. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep.1996;45(RR-12):1\u201335"},{"key":"2021121003422376700_R12","unstructured":"Zaloga GP, Chernow B. Life-threatening anaphylactic reaction to tetanus toxoid. Ann Allergy.1982;49:107\u2013108"},{"key":"2021121003422376700_R13","doi-asserted-by":"crossref","unstructured":"Leung AK. Anaphylaxis to DPT vaccine [letter]. J R Soc Med.1985;78:175","DOI":"10.1177\/014107688507800227"},{"key":"2021121003422376700_R14","doi-asserted-by":"crossref","unstructured":"Lleonart-Bellfill R, Cistero-Bahima A, Cerda-Trias MT, Olive-Perez A. Tetanus toxoid anaphylaxis [letter]. DICP.1991;25:870","DOI":"10.1177\/106002809102500730"},{"key":"2021121003422376700_R15","doi-asserted-by":"crossref","unstructured":"Pollock TM, Morris J. A 7-year survey of disorders attributed to vaccination in North West Thames region. Lancet.1983;1:753\u2013757","DOI":"10.1016\/S0140-6736(83)92037-8"},{"key":"2021121003422376700_R16","doi-asserted-by":"crossref","unstructured":"Wise RP, Salive ME, Braun MM, et al. Postlicensure safety surveillance for varicella vaccine. JAMA.2000;284:1271\u20131279 (published erratum appears in JAMA. 2000;284:3129)","DOI":"10.1001\/jama.284.10.1271"},{"key":"2021121003422376700_R17","doi-asserted-by":"crossref","unstructured":"Kwittken PL, Rosen S, Sweinberg SK. MMR vaccine and neomycin allergy [letter]. Am J Dis Child.1993;147:128\u2013129","DOI":"10.1001\/archpedi.1993.02160260018005"},{"key":"2021121003422376700_R18","doi-asserted-by":"crossref","unstructured":"Lear JT, English JS. Anaphylaxis after hepatitis B vaccination [letter]. Lancet.1995;345:1249","DOI":"10.1016\/S0140-6736(95)92039-0"},{"key":"2021121003422376700_R19","unstructured":"Atkinson A, Wolfe C, eds. Epidemiology and Prevention of Vaccine-Preventable Diseases. 7th ed. Atlanta, GA: Centers for Disease Control and Prevention, US Department of Health and Human Services; 2002"},{"key":"2021121003422376700_R20","unstructured":"Carey AB, Meltzer EO. Diagnosis and \u201cdesensitization\u201d in tetanus vaccine hypersensitivity. Ann Allergy.1992;69:336\u2013338"},{"key":"2021121003422376700_R21","doi-asserted-by":"crossref","unstructured":"Uriel AJ, Boyter AC, MacConnachie AM, Nathwani D. Immunisation against tetanus, in a hypersensitive individual, using a graded dosing regimen [letter]. J Infect.1995;30:83\u201384","DOI":"10.1016\/S0163-4453(95)93081-7"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/112\/4\/815\/1013676\/pe1003000815.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/112\/4\/815\/1013676\/pe1003000815.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T10:52:15Z","timestamp":1639133535000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/112\/4\/815\/63454\/Risk-of-Anaphylaxis-After-Vaccination-of-Children"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,10,1]]},"references-count":21,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2003,10,1]]},"published-print":{"date-parts":[[2003,10,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.112.4.815","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,10,1]]}}}